Health TrialsbyHealthPanel

Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI

ConditionsGliomaBrain Metastases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Paul Strauss

About this trial

Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions.

Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Preoperative evaluation of a cerebral expansion lesion

Evaluation of glioma recurrences

Evaluation of brain metastases

Evaluation of recurrence of metastases

Disqualifiers

Contraindication to the realization of an MRI

Minor or patients placed under guardianship or supervision

Patients deprived of liberty

Patients placed under judicial protection

Trial design

Design model

Single group

Treatments tested in this trial

  • Additional CEST sequences during PET/MRI exam

    Other intervention

    CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare

Treatment groups

800 Participants
are divided into 1 treatment group
Group A: Patients with glioma or brain metastasesOther 1 intervention

Trial outcomes

Primary outcomes

1

Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases

Evaluation at the cerebral level on the acquisition images of residual volume in MRI

Time frame
through study completion, up to 14 years
2

Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases

Evaluation at the cerebral level on the acquisition images of tumoral metabolic activity in PET

Time frame
through study completion, up to 14 years

Secondary outcomes

1

Correlate intratissular pH mapping and location of recurrence

Time frame
through study follow-up, up to 10 years
2

Correlate average pH of the tumor and histopathology

Time frame
through study follow-up, up to 10 years
3

Correlate average pH of the tumor and Disease-Free Survival (DFS)

Time frame
through study follow-up, up to 10 years
4

Correlate average pH of the tumor and Overall survival (OS)

Time frame
through study follow-up, up to 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Paul Strauss

Lead sponsor

Source ClinicalTrials.gov
Apply now